Novavax Taps Ex-AstraZeneca Executive as CMO, Will Head Corornavirus Vaccine Development
Novavax (NASDAQ: NVAX) has a new, high-powered chief medical officer (CMO). The company announced Wednesday that it appointed Filip Dubovsky to the position. An industry veteran with more than 20 years of experience, he was most recently deputy CMO for clinical affairs at another global pharmaceutical major, AstraZeneca (NYSE: AZN).
Most of Dubovsky's time at AstraZeneca was spent in its MedImmune biologics subsidiary. The MedImmune brand was retired by AstraZeneca last year; at that point, according to his LinkedIn profile page, Dubovsky had worked there for more than 13 years. He served in several executive positions, including vice-president of clinical development for vaccines and infectious disease.
Prior to that, he was scientific director of PATH Malaria Vaccine Initiative, where in his words, he "created, managed and defended a portfolio of 25 malaria vaccine candidates spanning from early candidate optimization to Phase 3 clinical study preparation."
Source Fool.com
